|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou XD, Tang ZY, Yang BH, Lin ZY, Ma ZC,
Ye SL, Wu ZQ, Fan J, Qin LX and Zheng BH: Experience of 1000
patients who underwent hepatectomy for small hepatocellular
carcinoma. Cancer. 91:1479–1486. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Raphael S Waly, Yangde Z and Yuxiang C:
Hepatocellular carcinoma: Focus on different aspects of management.
ISRN Oncol. 2012:421673. 2012.PubMed/NCBI
|
|
5
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Puisieux A, Brabletz T and Caramel J:
Oncogenic roles of EMT-inducing transcription factors. Nat Cell
Biol. 16:488–494. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guerram M, Jiang ZZ, Yousef BA, Hamdi AM,
Hassan HM, Yuan ZQ, Luo HW, Zhu X and Zhang LY: The potential
utility of acetyltanshinone IIA in the treatment of
HER2-overexpressed breast cancer: Induction of cancer cell death by
targeting apoptotic and metabolic signaling pathways. Oncotarget.
6:21865–21877. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lam W, Jiang Z, Guan F, Huang X, Hu R,
Wang J, Bussom S, Liu SH, Zhao H, Yen Y, et al: PHY906(KD018), an
adjuvant based on a 1800-year-old Chinese medicine, enhanced the
anti-tumor activity of Sorafenib by changing the tumor
microenvironment. Sci Rep. 5:93842015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang XY, Wang L, Huang ZL, Zheng Q, Li QS
and Tang ZY: Herbal extract ‘Songyou Yin’ inhibits tumor growth and
prolongs survival in nude mice bearing human hepatocellular
carcinoma xenograft with high metastatic potential. J Cancer Res
Clin Oncol. 135:1245–1255. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jia QA, Ren ZG, Bu Y, Wang ZM, Zhang QB,
Liang L, Jiang XM, Zhang QB and Tang ZY: Herbal compound ‘Songyou
Yin’ renders hepatocellular carcinoma sensitive to oxaliplatin
through inhibition of stemness. Evid Based Complement Alternat Med.
2012:9086012012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li X, Qu L, Dong Y, Han L, Liu E, Fang S,
Zhang Y and Wang T: A review of recent research progress on the
astragalus genus. Molecules. 19:18850–18880. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Boye A, Wu C, Jiang Y, Wang J, Wu J, Yang
X and Yang Y: Compound Astragalus and Salvia miltiorrhiza extracts
modulate MAPK-regulated TGF-β/Smad signaling in hepatocellular
carcinoma by multi-target mechanism. J Ethnopharmacol. 169:219–228.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Y, Auyeung KK, Zhang X and Ko JK:
Astragalus saponins modulates colon cancer development by
regulating calpain-mediated glucose-regulated protein expression.
BMC Complement Altern Med. 14:401. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Auyeung KK, Han QB and Ko JK: Astragalus
membranaceus: A Review of its protection against inflammation and
gastrointestinal cancers. Am J Chin Med. 44:1–22. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li W and Fitzloff JF: Determination of
astragaloside IV in Radix astragali (Astragalus membranaceus var.
monghulicus) using high-performance liquid chromatography with
evaporative light-scattering detection. J Chromatogr Sci.
39:459–462. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lai PK, Chan JY, Cheng L, Lau CP, Han SQ,
Leung PC, Fung KP and Lau CB: Isolation of anti-inflammatory
fractions and compounds from the root of Astragalus membranaceus.
Phytother Res. 27:581–587. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao M, Zhao J, He G, Sun X, Huang X and
Hao L: Effects of astragaloside IV on action potentials and ionic
currents in guinea-pig ventricular myocytes. Biol Pharm Bull.
36:515–521. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang L, Li Z, He W, Xu L, Wang J, Shi J
and Sheng M: Effects of astragaloside IV against the TGF-β1-induced
epithelial-to-mesenchymal transition in peritoneal mesothelial
cells by promoting Smad 7 expression. Cell Physiol Biochem.
37:43–54. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qi W, Niu J, Qin Q, Qiao Z and Gu Y:
Astragaloside IV attenuates glycated albumin-induced
epithelial-to-mesenchymal transition by inhibiting oxidative stress
in renal proximal tubular cells. Cell Stress Chaperones.
19:105–114. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xiong W, Ren ZG, Qiu SJ, Sun HC, Wang L,
Liu BB, Li QS, Zhang W, Zhu XD, Liu L, et al: Residual
hepatocellular carcinoma after oxaliplatin treatment has increased
metastatic potential in a nude mouse model and is attenuated by
Songyou Yin. BMC Cancer. 10:219. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY,
Chen J and Xue Q: New human hepatocellular carcinoma (HCC) cell
line with highly metastatic potential (MHCC97) and its expressions
of the factors associated with metastasis. Br J Cancer. 81:814–821.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xue G, Restuccia DF, Lan Q, Hynx D,
Dirnhofer S, Hess D, Rüegg C and Hemmings BA: Akt/PKB-mediated
phosphorylation of Twist1 promotes tumor metastasis via mediating
cross-talk between PI3K/Akt and TGF-β signaling axes. Cancer
Discov. 2:248–259. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hsu CY, Lin CH, Jan YH, Su CY, Yao YC,
Cheng HC, Hsu TI, Wang PS, Su WP, Yang CJ, et al:
Huntingtin-interacting protein-1 is an early-stage prognostic
biomarker of lung adenocarcinoma and suppresses metastasis via
Akt-mediated epithelial-mesenchymal transition. Am J Respir Crit
Care Med. 193:869–880. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen HN, Yuan K, Xie N, Wang K, Huang Z,
Chen Y, Dou Q, Wu M, Nice EC, Zhou ZG, et al: PDLIM1 stabilizes the
E-cadherin/β-catenin complex to prevent epithelial-mesenchymal
transition and metastatic potential of colorectal cancer cells.
Cancer Res. 76:1122–1134. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Murata-Kamiya N, Kurashima Y, Teishikata
Y, Yamahashi Y, Saito Y, Higashi H, Aburatani H, Akiyama T, Peek RM
Jr, Azuma T, et al: Helicobacter pylori CagA interacts with
E-cadherin and deregulates the β-catenin signal that promotes
intestinal transdifferentiation in gastric epithelial cells.
Oncogene. 26:4617–4626. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rhodes N, Heerding DA, Duckett DR,
Eberwein DJ, Knick VB, Lansing TJ, McConnell RT, Gilmer TM, Zhang
SY, Robell K, et al: Characterization of an Akt kinase inhibitor
with potent pharmacodynamic and antitumor activity. Cancer Res.
68:2366–2374. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Levy DS, Kahana JA and Kumar R: AKT
inhibitor, GSK690693, induces growth inhibition and apoptosis in
acute lymphoblastic leukemia cell lines. Blood. 113:1723–1729.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang J, Wang P, Ouyang H, Yin J, Liu A,
Ma C and Liu L: Targeting cancer-related inflammation: Chinese
herbal medicine inhibits epithelial-to-mesenchymal transition in
pancreatic cancer. PLoS One. 8:e703342013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qi X, Zhang L and Lu X: New insights into
the epithelial-to-mesenchymal transition in cancer. Trends
Pharmacol Sci. 37:246–248. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lai YJ and Tai CJ, Wang CW, Choong CY, Lee
BH, Shi YC and Tai CJ: Anti-cancer activity of Solanum nigrum
(AESN) through suppression of mitochondrial function and
epithelial-mesenchymal transition (EMT) in breast cancer cells.
Molecules. 21:pii: E5532016. View Article : Google Scholar
|
|
33
|
Lin W, Zhuang Q, Zheng L, Cao Z, Shen A,
Li Q, Fu C, Feng J and Peng J: Pien Tze Huang inhibits liver
metastasis by targeting TGF-β signaling in an orthotopic model of
colorectal cancer. Oncol Rep. 33:1922–1928. 2015.PubMed/NCBI
|
|
34
|
Lin X, Yi Z, Diao J, Shao M, Zhao L, Cai
H, Fan Q, Yao X and Sun X: ShaoYao decoction ameliorates
colitis-associated colorectal cancer by downregulating
proinflammatory cytokines and promoting epithelial-mesenchymal
transition. J Transl Med. 12:105. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li Y, Chen CQ, He YL, Cai SR, Yang DJ, He
WL, Xu JB and Zan WH: Abnormal expression of E-cadherin in tumor
cells is associated with poor prognosis of gastric carcinoma. J
Surg Oncol. 106:304–310. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Siu MK, Wong ES, Kong DS, Chan HY, Jiang
L, Wong OG, Lam EW, Chan KK, Ngan HY, Le XF, et al: Stem cell
transcription factor NANOG controls cell migration and invasion via
dysregulation of E-cadherin and FoxJ1 and contributes to adverse
clinical outcome in ovarian cancers. Oncogene. 32:3500–3509. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Qualtrough D, Rees P, Speight B, Williams
AC and Paraskeva C: The Hedgehog inhibitor cyclopamine reduces
β-catenin-Tcf transcriptional activity, induces E-cadherin
expression, and reduces invasion in colorectal cancer cells.
Cancers. 7:1885–1899. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang SP, Wang WL, Chang YL, Wu CT, Chao
YC, Kao SH, Yuan A, Lin CW, Yang SC, Chan WK, et al: p53 controls
cancer cell invasion by inducing the MDM2-mediated degradation of
Slug. Nat Cell Biol. 11:694–704. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fernando RI, Litzinger M, Trono P,
Hamilton DH, Schlom J and Palena C: The T-box transcription factor
Brachyury promotes epithelial-mesenchymal transition in human tumor
cells. J Clin Invest. 120:533–544. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lee JK, Phillips JW, Smith BA, Park JW,
Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG,
Mathis C, et al: N-Myc drives neuroendocrine prostate cancer
initiated from human prostate epithelial cells. Cancer Cell.
29:536–547. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Toker A and Rameh L: PIPPing on AKT1: How
many phosphatases does it take to turn off PI3K? Cancer Cell.
28:143–145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mayer IA and Arteaga CL: The PI3K/AKT
pathway as a target for cancer treatment. Annu Rev Med. 67:11–28.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Attoub S, Arafat K, Hammadi NK, Mester J
and Gaben AM: Akt2 knock-down reveals its contribution to human
lung cancer cell proliferation, growth, motility, invasion and
endothelial cell tube formation. Sci Rep. 5:127592015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang Y, Liu S, Wang L, Wu Y, Hao J, Wang
Z, Lu W, Wang XA, Zhang F, Cao Y, et al: A novel PI3K/AKT signaling
axis mediates Nectin-4-induced gallbladder cancer cell
proliferation, metastasis and tumor growth. Cancer Lett.
375:179–189. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Larue L and Bellacosa A:
Epithelial-mesenchymal transition in development and cancer: Role
of phosphatidylinositol 3 kinase/AKT pathways. Oncogene.
24:7443–7454. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gu Y, Wang Q, Guo K, Qin W, Liao W, Wang
S, Ding Y and Lin J: TUSC3 promotes colorectal cancer progression
and epithelial-mesenchymal transition (EMT) through WNT/β-catenin
and MAPK signalling. J Pathol. 239:60–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lee SC, Kim OH, Lee SK and Kim SJ: IWR-1
inhibits epithelial-mesenchymal transition of colorectal cancer
cells through suppressing Wnt/β-catenin signaling as well as
survivin expression. Oncotarget. 6:27146–27159. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bernaudo S, Salem M, Qi X, Zhou W, Zhang
C, Yang W, Rosman D, Deng Z, Ye G, Yang B, et al: Cyclin G2
inhibits epithelial-to-mesenchymal transition by disrupting
Wnt/β-catenin signaling. Oncogene. 35:4816–4827. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Soutto M, Peng D, Katsha A, Chen Z,
Piazuelo MB, Washington MK, Belkhiri A, Correa P and El-Rifai W:
Activation of β-catenin signalling by TFF1 loss promotes cell
proliferation and gastric tumorigenesis. Gut. 64:1028–1039. 2015.
View Article : Google Scholar : PubMed/NCBI
|
